What Is Saxenda?

1. What Is Saxenda?

Saxenda is a Novo Nordisk prescription brand for liraglutide injection. The current DailyMed Saxenda label describes Saxenda as a glucagon-like peptide-1, or GLP-1, receptor agonist indicated with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in defined adult and pediatric populations.

That sentence packs several different facts into one label summary. “Saxenda” is the brand. “Liraglutide” is the active ingredient. “GLP-1 receptor agonist” is the class wording. “Chronic weight management” is the broad public label context. None of those words, by itself, tells a person what to take, how to take it, whether to switch products, or whether a product is appropriate.

The official Saxenda patient site and NovoMedLink physician page use similar framing: Saxenda is liraglutide injection in a weight-management context. This page uses those sources only to explain terminology, not to restate administration instructions.

For broader category background, see What Is a GLP-1?. For the molecule behind Saxenda, see What Is Liraglutide?.

2. Why Is Liraglutide the Important Word?

Liraglutide is the active ingredient in Saxenda. DailyMed identifies Saxenda as liraglutide injection and as a GLP-1 receptor agonist. That makes liraglutide the molecule-level answer, while Saxenda is the brand-and-label answer.

This distinction is useful because GLP-1 articles often mix several layers of naming. A person may see “Saxenda,” “liraglutide,” “GLP-1,” “injection brand,” “weight-management medicine,” and “Novo Nordisk” in the same paragraph. Those phrases are related, but they are not interchangeable.

The clean naming stack looks like this:

Keeping those layers separate prevents a common mistake: treating a brand name as if it answers every question about molecule, route, indication, patient population, label changes, and clinical decision-making.

3. What Does the Current U.S. Label Say?

The current U.S. Saxenda label says Saxenda is used in combination with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition.

That is label context, not an eligibility checklist for readers. This article does not interpret BMI, comorbidities, age, weight, symptoms, lab values, insurance criteria, or whether any person fits a labeled population.

The adolescent wording is worth mentioning because it is part of official U.S. history. FDA announced on December 4, 2020, that Saxenda received a supplemental indication for chronic weight management among pediatric patients aged 12 and older who meet the label’s obesity and weight wording. FDA also noted that Saxenda had been approved since December 2014 for chronic weight management in adults with obesity or adults with overweight and at least one weight-related condition.

The practical takeaway is narrow: Saxenda is not only an adult-brand headline in current U.S. label sources. Pediatric context exists, but only inside specific label wording. A general explainer can note that label context without turning it into advice for adolescents, parents, clinicians, or prescribers.

4. How Is Saxenda Different From Victoza?

Saxenda and Victoza both involve liraglutide, but they are different brand contexts. The current DailyMed Victoza label describes Victoza as a GLP-1 receptor agonist for type 2 diabetes glycemic-control use in adults and pediatric patients aged 10 years and older, plus cardiovascular-risk language for defined adults with type 2 diabetes and established cardiovascular disease.

That is a different public lane from Saxenda. Saxenda is the liraglutide brand people usually encounter in chronic weight-management contexts. Victoza is the liraglutide brand people usually encounter in type 2 diabetes contexts. “Same active ingredient” is true, but it does not collapse the labels into one product story.

This is why the phrase “liraglutide brand” needs a second sentence. Saxenda and Victoza are both liraglutide brands. They do not have the same brand positioning, label population, or public meaning. A careful record or article should name the brand, the active ingredient, and the source checked.

For the molecule-first explanation, read What Is Liraglutide?. For the companion brand context, see What Is Victoza?.

5. How Is Saxenda Different From Wegovy and Ozempic?

Saxenda contains liraglutide. Wegovy and Ozempic are semaglutide brand contexts. That active-ingredient difference is the simplest way to stop the names from blurring together.

The brand contexts differ too. Saxenda is a liraglutide brand centered on chronic weight management. Wegovy is a semaglutide brand centered on weight-management and related labeled contexts. Ozempic is a semaglutide brand centered on type 2 diabetes and related labeled contexts. Semaglutide is the molecule behind Wegovy, Ozempic, and Rybelsus, not the molecule behind Saxenda.

The point is precision, not ranking. This page does not say Saxenda is better, worse, older in a way that matters clinically, easier to use, harder to use, more appropriate, or less appropriate than a semaglutide product. Those would be product-selection or medical questions.

The useful educational sentence is simpler: Saxenda and Wegovy are both well-known GLP-1 weight-management brand names, but they do not contain the same active ingredient.

6. How Is Saxenda Different From Zepbound and Mounjaro?

Saxenda also differs from tirzepatide brands. Zepbound and Mounjaro contain tirzepatide, not liraglutide. Current tirzepatide labels use GIP receptor and GLP-1 receptor agonist language, while Saxenda’s label identifies liraglutide as a GLP-1 receptor agonist.

That receptor-language distinction is easy to lose in public shorthand. Media and social posts often call many metabolic drugs “GLP-1s.” That can be understandable in casual conversation, but it is incomplete for tirzepatide because the label includes both GIP and GLP-1 receptor language.

A careful brand map looks like this:

This table is not a treatment comparison. It only separates names so readers can avoid treating molecule names, brand names, and class shorthand as if they were the same kind of fact.

7. Why Saxenda Still Matters in GLP-1 Search

Saxenda still matters because it connects several eras of GLP-1 language. It is a Novo Nordisk liraglutide brand, it predates the current wave of semaglutide and tirzepatide attention, and FDA’s adolescent update gives it a documented place in chronic weight-management approval history.

That history can be more useful than another “which is best?” comparison. Saxenda shows how one active ingredient can appear under different brand contexts, how labels can change over time, and how public search language often lags behind regulated source language.

It also shows why source dates matter. The DailyMed Saxenda page reviewed for this article was updated February 25, 2026, and lists recent label changes in 2025 and 2026. A page written from memory, or from an older press release alone, could miss current label wording.

For readers, the durable habit is to ask five questions before trusting a claim:

• Which brand is being discussed?
• Which active ingredient is named?
• Which official label or source is being used?
• Which population or public context is the source describing?
• Is the source explaining a label fact or giving personal medical advice?

Those questions make Saxenda easier to understand without turning the page into prescribing guidance.

8. Sources

9. What Is Saxenda FAQ

• What is Saxenda in simple terms?

  Saxenda is a Novo Nordisk brand name for liraglutide injection. Current U.S. labeling describes Saxenda as a GLP-1 receptor agonist used in chronic weight-management contexts for defined adult and pediatric populations.

• Is Saxenda the same thing as liraglutide?

  No. Liraglutide is the active ingredient. Saxenda is a brand name and label context for liraglutide injection. Victoza also contains liraglutide, but it is a different brand with a type 2 diabetes label context.

• How is Saxenda different from Victoza?

  Saxenda and Victoza both involve liraglutide, but current U.S. labels point to different public contexts. Saxenda is framed around chronic weight management, while Victoza is framed around type 2 diabetes and certain cardiovascular-risk language in adults with type 2 diabetes.

• How is Saxenda different from Wegovy, Ozempic, or Zepbound?

  Saxenda contains liraglutide. Wegovy and Ozempic are semaglutide brand contexts, and Zepbound contains tirzepatide. Those names differ by active ingredient, brand, receptor-language details, route and label context; this article does not rank or recommend products.